ICU Medical (ICUI) Releases FY 2018 Earnings Guidance

ICU Medical (NASDAQ:ICUI) issued an update on its FY 2018 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $8.45-8.85 for the period, compared to the Thomson Reuters consensus estimate of $8.60.

ICU Medical stock traded up $0.74 during midday trading on Thursday, hitting $260.24. 469,940 shares of the stock were exchanged, compared to its average volume of 161,462. ICU Medical has a 52 week low of $180.45 and a 52 week high of $321.70. The firm has a market capitalization of $5.28 billion, a price-to-earnings ratio of 47.14 and a beta of 0.65.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Thursday, August 9th. The medical instruments supplier reported $2.66 earnings per share for the quarter, topping the consensus estimate of $1.82 by $0.84. ICU Medical had a net margin of 5.93% and a return on equity of 12.78%. The business had revenue of $360.46 million for the quarter, compared to analyst estimates of $337.60 million. During the same quarter last year, the firm earned $0.76 EPS. ICU Medical’s quarterly revenue was up 8.7% compared to the same quarter last year. As a group, research analysts anticipate that ICU Medical will post 7.6 EPS for the current fiscal year.

Several analysts have commented on ICUI shares. ValuEngine downgraded shares of ICU Medical from a buy rating to a hold rating in a report on Tuesday, September 18th. TheStreet upgraded shares of ICU Medical from a c+ rating to a b+ rating in a report on Monday, August 20th. BidaskClub downgraded shares of ICU Medical from a buy rating to a hold rating in a report on Thursday. Finally, Zacks Investment Research downgraded shares of ICU Medical from a buy rating to a hold rating in a report on Wednesday, July 11th.

In other news, VP Virginia Ruth Sanzone sold 787 shares of ICU Medical stock in a transaction that occurred on Tuesday, August 28th. The shares were sold at an average price of $303.12, for a total value of $238,555.44. Following the sale, the vice president now directly owns 1,367 shares in the company, valued at $414,365.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Pfizer Inc sold 700,000 shares of ICU Medical stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $284.35, for a total transaction of $199,045,000.00. The disclosure for this sale can be found here. Insiders sold 711,920 shares of company stock worth $202,651,956 over the last quarter. 12.50% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by WKRB News and is the sole property of of WKRB News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.wkrb13.com/2018/11/08/icu-medical-icui-releases-fy-2018-earnings-guidance.html.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.

Further Reading: Marijuana Stocks

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply